(Q33365485)

English

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Shinji Urakami

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tateki Yoshino

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nobuyuki Kikuno

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shin Imai

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Satoshi Honda

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tatuaki Yoneda

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hirofumi Kishi

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kazushi Shigeno

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hiroaki Shiina

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mikio Igawa

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

65

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

543-548

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chemotherapy for androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Intermittent chemotherapy in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.10.033

7 January 2021

Identifiers

10.1016/J.UROLOGY.2004.10.033

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

release_xdct5dnrcjedfjrgt6vorlrchq

1 reference

https://api.fatcat.wiki/v0/release/xdct5dnrcjedfjrgt6vorlrchq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33365485&oldid=1966852598"